NRX Pharma Advances Toward FDA Approval for Preservative-Free Ketamine Drug

NRX Pharmaceuticals announced progress toward FDA approval after receiving confirmation that no bioequivalence deficiencies were identified for its new drug application. The determination, while preliminary, supports the company’s pathway toward a potential approval expected as early as summer 2026.

The proposed treatment is notable as the first ketamine formulation without benzothonium chloride, a preservative associated with toxicity, potentially offering a safer alternative for patients and marking a significant innovation in the ketamine-based therapeutics market.

#NRXPharmaceuticals
#Biotech
#FDAApproval
#Ketamine
#MentalHealth
#Pharmaceuticals
#DrugDevelopment
#HealthcareInnovation
#BiotechInvesting
#ClinicalResearch
#FDA
#MedicalInnovation
#JaneKing
#NewsOut